Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

sclosed sales milestones, and tiered, double-digit royalties on global revenues.  Ambit also has an option to co-promote products in the U.S. where Astellas and Ambit share equally all profits and losses generated from U.S. sales.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications.  Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML.  Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.  In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor. Ambit also has a preclinical candidate, CEP-32496, and a BRAF inhibitor licensed to Cephalon.  For more information, visit www.ambitbio.com.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,800 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, and DM complications and Metabolic Diseases. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.

Contacts:
Ambit Biosciences:
Alan Fuhrman
Chie
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... analysis for various reagents used in the ... is driving the life science reagents market ... study include manufacturers and providers of life ... Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , ...
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... blood, termed ,endometrial regenerative cells, (ERCs) are capable ... of advanced peripheral artery disease. A study published ... Translational Medicine demonstrates that when circulation-blocked mice were ... restored. , Critical limb ischemia, an ...
... SAN JOSE, Calif., Aug. 18 VNUS(R) Medical,Technologies, ... quarter results and,revises its full year 2008 guidance. ... operating expenses and certain balance sheet accounts,to record ... appropriately recorded in prior periods since the adoption ...
... (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company,focused on ... ended June 30, 2008., Net loss was $3.8 ... June 30, 2008, compared to $0.5 million, or $0.05 ... was $7.5 million, or $0.65 per share, for the,six ...
Cached Biology Technology:Limbs saved by menstrual blood stem cells 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 3VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 2Arno Therapeutics Announces Second Quarter 2008 Financial Results 3Arno Therapeutics Announces Second Quarter 2008 Financial Results 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 5
(Date:7/14/2014)... to the discovery and description of Rhipidocyrtus muiri ... turned out to represent a new genus and species. The ... from Borneo is discussed in a recent paper published in ... The holotype male, and only known specimen of Rhipidocyrtus ... subsequent to this it was transferred among several researchers in ...
(Date:7/14/2014)... consequence of aging? , Although it is widely thought ... risk of developing several common cancers decreases with age. ... decrease with age in the risk of developing certain ... puzzle was presented in a recent paper published in ... P. Brody of the Department of Biomedical Engineering at ...
(Date:7/13/2014)... A new study in women suggests that experiencing one ... single high-fat meal can slow the body,s metabolism, potentially ... about the previous day,s stressors before giving them a ... fat. The scientists then measured their metabolic rate ... and fat and took measures of blood sugar, ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... the most common childhood cancer is cured in about ... number was closer to five percent. In efforts to ... Children's Research Hospital, the University of Tennessee, and the ... play a role in the effectiveness of chemotherapy drugs. ...
... nanotubes make an ideal scaffold for the growth of bone ... broken bones, allowing them to simply inject a solution of ... appears in the June 14 issue of the American Chemical ... scientific society. , The success of a bone graft depends ...
... primordial soup that produced life on earth, there were ... acid chains, which were the first elements able to ... these molecules were ribonucleic acid (RNA) chains, a molecule ... has the secondary role in cells of copying information ...
Cached Biology News:Genes linked to treatment resistance in children with leukemia 2Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3Life's origins were easier than was thought 2
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
... BalanceTalk XL provides balance data collection and ... Complete integration with Microsoft Excel , ... moisture analyzers , New balances can be added ... Collect data from multiple balances into one spreadsheet ...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Biology Products: